Related Experiment Videos
Selective serotonin reuptake inhibitors and the risk for suicidality in adolescents: an update
Lucas Giner1, C Matthew Nichols, Gil Zalsman
1Puerta de Hierro Hospital, Universidad Autonoma de Madrid, Madrid, Spain. lginer@neuron.cpmc.columbia.edu
Abstract:
The controversy regarding Selective Serotonin Reuptake Inhibitors (SSRIs) and suicidality dates back to the early 1990s. The first agent reported to be associated with suicidality was fluoxotine. In 2003, the British Medicines and Healthcare Products Regulatory Agency (MHRA) warned about possible risk of suicidality in children and adolescents treated with paroxetine for Major Depressive Disorder (MDD). This warning was soon extended to all the SSRIs as well as venlafaxine and mirtazapine. Similarly, the United States Food and Drug Administration (FDA) issued a "black box warning" on these medications in 2004. We address the debate concerning this warning and its clinical implications and review the latest contributions to the literature.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: Overview
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Drug Therapy
Antianxiety Medications
Anxiolytic Drugs: Overview
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic circuitry.